IT1270939B - Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili. - Google Patents

Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.

Info

Publication number
IT1270939B
IT1270939B ITRM930301A ITRM930301A IT1270939B IT 1270939 B IT1270939 B IT 1270939B IT RM930301 A ITRM930301 A IT RM930301A IT RM930301 A ITRM930301 A IT RM930301A IT 1270939 B IT1270939 B IT 1270939B
Authority
IT
Italy
Prior art keywords
organism
fragments
derivatives
disease
antigen
Prior art date
Application number
ITRM930301A
Other languages
English (en)
Inventor
Franco Felici
Alessandra Luzzago
Paolo Monaci
Alfredo Nicosia
Riccardo Cortese
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11401749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT1270939(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Priority to ITRM930301A priority Critical patent/IT1270939B/it
Publication of ITRM930301A0 publication Critical patent/ITRM930301A0/it
Priority to RU95122726A priority patent/RU2136697C1/ru
Priority to DE69413024T priority patent/DE69413024T2/de
Priority to US08/553,257 priority patent/US5994083A/en
Priority to CN94192060A priority patent/CN1093881C/zh
Priority to JP6525217A priority patent/JP2813468B2/ja
Priority to AU68069/94A priority patent/AU685121B2/en
Priority to PCT/IT1994/000054 priority patent/WO1994026886A2/en
Priority to AT94916385T priority patent/ATE170558T1/de
Priority to CA002160486A priority patent/CA2160486C/en
Priority to BR9406595A priority patent/BR9406595A/pt
Priority to ES94916385T priority patent/ES2120046T3/es
Priority to EP94916385A priority patent/EP0698091B1/en
Priority to DK94916385T priority patent/DK0698091T3/da
Priority to HK98112929.4A priority patent/HK1011710B/en
Publication of ITRM930301A1 publication Critical patent/ITRM930301A1/it
Publication of IT1270939B publication Critical patent/IT1270939B/it
Application granted granted Critical
Priority to US09/441,992 priority patent/US6541210B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Procedimento per la preparazione di immunogeni o reagenti diagnostici che mimano un antigene o un organismo patogeno specifici di una malattia, caratterizzato essenzialmente dalle seguenti operazioni:- identificazioni di almeno un anticorpo che reagisce con l'antigene o l'organismo patogeno specifici della malattia.- costruzione di librerie di fagi che espongono sulla superficie del capside oligopeptidi, espressi da inserti oligonucleotidici a sequenza casuale introdotti in un gene codificante per il capside fagico con tecniche di manipolazione genetica (ad esempio utilizzando un plasmide ingegnerizzato per le finalità dell'invenzione, una porzione della cui mappa genetica è mostrata in figura);- selezione dei fagi che espongono sulla superficie del capside oligopeptidi antigenici riconosciuti da detto anticorpo;- eventuale uso dei fagi selezionati e/o loro frammenti e/o loro derivati per la formulazione di kit diagnostici per lo specifico agente patogeno, o in genere per le malattie, inclusi i disordini immunologici tipici delle cosiddette malattie autoimmuni, da eziologia e/o patogenesi nota o ignota;- eventuale uso dei fagi selezionati e/o loro frammenti e/o loro derivati per la formulazione di un antagonista delle reazioni antigene-anticorpo per la cura della malattia indotta da detto antigene;- eventuale uso dei fagi selezionati e/o loro frammenti e/o loro derivati per indurre tolleranza nei fenomeni di ipersensibilità e/o allergia a composti e/o preparati naturali o sintetici;- eventuale immunizzazione di un organismo mediante i fagi selezionati e/o loro frammenti e/o loro derivati; e - eventuale verifica della presenza, nel siero dell'organismo immunizzato, di anticorpi che riconoscono il suddetto antigene o organismo specifici della malattia.
ITRM930301A 1993-05-11 1993-05-11 Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili. IT1270939B (it)

Priority Applications (16)

Application Number Priority Date Filing Date Title
ITRM930301A IT1270939B (it) 1993-05-11 1993-05-11 Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
HK98112929.4A HK1011710B (en) 1993-05-11 1994-05-05 Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable
PCT/IT1994/000054 WO1994026886A2 (en) 1993-05-11 1994-05-05 Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable
BR9406595A BR9406595A (pt) 1993-05-11 1994-05-05 Processo para a preparação dos imunógenos ou reagentes para diagnóstico que mimetizam um antigeno ou um organismo patogênico especifico para uma doença fagos vacinas contra um agente patogênico especifico e plasmideos pc89 modificados
US08/553,257 US5994083A (en) 1993-05-11 1994-05-05 Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable
CN94192060A CN1093881C (zh) 1993-05-11 1994-05-05 免疫原或诊断剂的制备及其获得免疫原或诊断试剂的方法
JP6525217A JP2813468B2 (ja) 1993-05-11 1994-05-05 免疫原または診断試薬の製造法、およびその方法によって得られる免疫原または診断試薬
AU68069/94A AU685121B2 (en) 1993-05-11 1994-05-05 Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable
RU95122726A RU2136697C1 (ru) 1993-05-11 1994-05-05 Способ получения олигопептидов
AT94916385T ATE170558T1 (de) 1993-05-11 1994-05-05 Verfahren zur herstellung von immunogenen oder diagnostischen reagentien und ebensolche
CA002160486A CA2160486C (en) 1993-05-11 1994-05-05 Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable
DE69413024T DE69413024T2 (de) 1993-05-11 1994-05-05 Verfahren zur herstellung von immunogenen oder diagnostischen reagentien und ebensolche
ES94916385T ES2120046T3 (es) 1993-05-11 1994-05-05 Procedimiento de preparacion de inmunogenos o reactivos de diagnostico e inmunogenos o reactivos de diagnostico obtenibles por dicho procedimiento.
EP94916385A EP0698091B1 (en) 1993-05-11 1994-05-05 Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable
DK94916385T DK0698091T3 (da) 1993-05-11 1994-05-05 Fremgangsmåde til fremstilling af immunogener eller diagnostiske reagenser samt immunogener eller diagnostiske reagenser op
US09/441,992 US6541210B1 (en) 1993-05-11 1999-11-18 Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM930301A IT1270939B (it) 1993-05-11 1993-05-11 Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.

Publications (3)

Publication Number Publication Date
ITRM930301A0 ITRM930301A0 (it) 1993-05-11
ITRM930301A1 ITRM930301A1 (it) 1994-11-11
IT1270939B true IT1270939B (it) 1997-05-26

Family

ID=11401749

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM930301A IT1270939B (it) 1993-05-11 1993-05-11 Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.

Country Status (14)

Country Link
US (2) US5994083A (it)
EP (1) EP0698091B1 (it)
JP (1) JP2813468B2 (it)
CN (1) CN1093881C (it)
AT (1) ATE170558T1 (it)
AU (1) AU685121B2 (it)
BR (1) BR9406595A (it)
CA (1) CA2160486C (it)
DE (1) DE69413024T2 (it)
DK (1) DK0698091T3 (it)
ES (1) ES2120046T3 (it)
IT (1) IT1270939B (it)
RU (1) RU2136697C1 (it)
WO (1) WO1994026886A2 (it)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492807A (en) 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
DE69629385T2 (de) * 1995-11-10 2004-06-09 Elan Corp. Plc Peptide, die den transport über gewebe erhöhen und verfahren zu ihrer identifizierung und verwendung
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US6696545B1 (en) * 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
FR2762601B3 (fr) 1997-04-29 1999-06-04 Bio Merieux Polypeptide capable de reagir avec les anticorps de patients atteints de sclerose en plaques et utilisations
IT1291913B1 (it) * 1997-05-22 1999-01-21 Angeletti P Ist Richerche Bio Metodo che prevede l'uso di batteriofagi per la rivelazione della presenza di molecole di interesse in campioni biologici
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6444787B1 (en) 1997-12-31 2002-09-03 Research Development Institute, Inc. Method of isolating a peptide which immunologically mimics microbial carbohydrates including group B streptococcal carbohydrates and the use thereof in a vaccine
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
US6413721B1 (en) 1998-07-24 2002-07-02 Her Majesty the Queen in Right of Canada, as represented by the “Canadian Food Inspection Agency” Methods of isolating common and specific antigens from excretory-secretory products of protostrongylidae
SE9803993D0 (sv) * 1998-11-23 1998-11-23 Bjoern Carlsson New reagent and use thereof
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
US9974847B2 (en) * 2000-08-24 2018-05-22 Immunitor USA, Inc. Treatment and prevention of tuberculosis
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
CN1880457B (zh) 2001-10-11 2010-05-26 麦克公司 Ad6重组核酸
CN1582337B (zh) * 2001-10-11 2011-12-14 默沙东公司 丙型肝炎病毒疫苗
DE60238633D1 (de) * 2001-11-09 2011-01-27 Angeletti P Ist Richerche Bio Screening auf inhibitoren des eindringens von hepatitis-c-virus
US8088569B2 (en) * 2002-03-01 2012-01-03 Applied Immune Technologies Immunogens for treatment of neoplastic and infectious disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004098529A2 (en) * 2003-04-30 2004-11-18 Emory University Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
JP5475279B2 (ja) * 2005-06-17 2014-04-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｃ型肝炎ウイルス核酸ワクチン
WO2007087758A2 (es) * 2006-01-31 2007-08-09 Centro De Ingenieria Genetica Y Biotecnologia Mimotopos de polisacáridos capsulares de neisseria meningitidis y formulaciones farmacéuticas
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
FR2910492B1 (fr) 2006-12-20 2013-02-15 Bio Modeling Systems Ou Bmsystems Procede de preparation de bacteriophages modifies par insertion de sequences aleatoires dans les proteines de ciblage desdits bacteriophages
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2627223T3 (es) * 2007-06-26 2017-07-27 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Presentación de agentes de unión
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN114230632B (zh) * 2021-09-18 2023-01-24 华南农业大学 一种丙烯酰胺衍生物模拟表位肽及应用
CN119859168B (zh) * 2025-03-21 2025-09-02 中国海洋大学 一种兼具ace和dpp-iv抑制活性的双功能活性肽及其制备方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575495A (en) * 1983-05-12 1986-03-11 New York Blood Center, Inc. Synthetic antigenic peptide derived from Hepatitis B surface antigen
JPH07119760B2 (ja) * 1984-07-24 1995-12-20 コモンウエルス・セ−ラム・ラボラトリ−ズ・コミッション ミモトープを検出または決定する方法
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
WO1986006487A1 (en) * 1985-04-22 1986-11-06 Commonwealth Serum Laboratories Commission Method for determining mimotopes
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
SU1612264A1 (ru) * 1989-03-01 1990-12-07 Институт биоорганической химии им.М.М.Шемякина Способ твердофазного иммуноферментного определени антител к вирусу иммунодефицита человека и меченный биотином синтетический пептид дл его осуществлени
US5182366A (en) * 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
CA2084307A1 (en) * 1990-06-01 1991-12-02 Cetus Oncology Corporation Compositions and methods for identifying biologically active molecules
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
IL99552A0 (en) * 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
IL99553A0 (en) * 1990-09-28 1992-08-18 Ixsys Inc Compositions containing oligonucleotides linked to expression elements,a kit for the preparation of vectors useful for the expression of a diverse population of random peptides and methods utilizing the same
GB9022190D0 (en) * 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
DE4122599C2 (de) * 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5492807A (en) * 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease

Also Published As

Publication number Publication date
JP2813468B2 (ja) 1998-10-22
CN1093881C (zh) 2002-11-06
CA2160486C (en) 2001-02-13
ES2120046T3 (es) 1998-10-16
ATE170558T1 (de) 1998-09-15
BR9406595A (pt) 1996-01-02
ITRM930301A0 (it) 1993-05-11
AU685121B2 (en) 1998-01-15
EP0698091B1 (en) 1998-09-02
DE69413024D1 (de) 1998-10-08
DK0698091T3 (da) 1999-06-07
JPH08506493A (ja) 1996-07-16
AU6806994A (en) 1994-12-12
EP0698091A1 (en) 1996-02-28
WO1994026886A2 (en) 1994-11-24
CA2160486A1 (en) 1994-11-24
ITRM930301A1 (it) 1994-11-11
DE69413024T2 (de) 1999-02-04
WO1994026886A3 (en) 1995-03-16
US6541210B1 (en) 2003-04-01
RU2136697C1 (ru) 1999-09-10
CN1122613A (zh) 1996-05-15
US5994083A (en) 1999-11-30
HK1011710A1 (en) 1999-07-16

Similar Documents

Publication Publication Date Title
IT1270939B (it) Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
Steer et al. Status of research and development of vaccines for Streptococcus pyogenes
Soybilgic et al. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years
Earnshaw et al. Analysis of anticentromere autoantibodies using cloned autoantigen CENP-B.
Naruse et al. Deposition of renal tubular epithelial antigen along the glomerular capillary walls of patients with membranous glomerulonephritis
RU95122726A (ru) Способ получения иммуногенов или диагностических реагентов, а также иммуногены и диагностические реагенты, получаемые с его помощью
BR0207067A (pt) Método para identificar, isolar e produzir antìgenos para um patógeno especìfico e uso do mesmo
PT744958E (pt) Bancos de anticorpos policlonais
Bukbuk et al. Prevalence of rubella-specific IgG antibody in non-immunized pregnant women in Maiduguri, north eastern Nigeria
Cunningham et al. Treatment of advanced cancer with active immunization
ES2155450T5 (es) Anticuerpos opsonicos fuertemente reactivos, que reaccionan a los antigenos comunes de los staphylococcus.
Donatsky Comparison of cellular and humoral immunity against streptococcal and adult human oral mucosa antigens in relation to exacerbation of recurrent aphthous stomatitis
Salmi et al. Measles virus antibody in cerebrospinal fluids from patients with multiple sclerosis
US9593150B2 (en) Immunoglobulin-binding human mycoplasma antigens and methods of use thereof
ATE335764T1 (de) Spezifische antikörper gegen humanes choriongonadotropin hormone und deren verwendung in therapie und diagnose
Renvoize et al. Cytomegalovirus infection and Alzheimer's disease
Ibrahim et al. Tumor-associated antigens in cervical cancer tissues and in sera from patients with cervical cancer or with head and neck cancer
Banks et al. Persistence of neutralizing antibody in adult volunteers immunized with adenovirus soluble antigens
Uibo et al. Autoantibodies in Estonia and Sweden, populations with different responses to allergens
JPS60138469A (ja) 腫瘍特異的免疫グロブリンの測定法
Lewis et al. Quantitation of secretory immunoglobulin A in chronic pulmonary disease
Fuchs et al. The nature of murine immune response to nucleic acids
Fuller et al. Affinity purification and refined structural characterization of terminal deoxynucleotidyltransferase
Bansil et al. Measles vaccination does not prevent multiple sclerosis
Byrnes et al. Competitive SARS-CoV-2 serology reveals most antibodies targeting the spike receptor-binding domain compete for ACE2 binding. mSphere 5: e00802-20

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970318